Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline in the Class Action Lawsuit against Accretive Health, Inc.

  Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline in the Class
  Action Lawsuit against Accretive Health, Inc.

Business Wire

LOS ANGELES -- July 3, 2013

Glancy Binkow & Goldberg LLP announces that all purchasers of the securities
of Accretive Health, Inc. (“Accretive” or the “Company”) (NYSE:AH) between May
20, 2010 and February 26, 2013 (the “Class Period’) have until July 19, 2013
to file a motion to be appointed as lead plaintiff in the shareholder lawsuit
filed in the United States District Court for the Northern District of
Illinois.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888)
773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU
PURCHASED ACCRETIVE STOCK PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL
PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES
PURCHASED.

The Complaint alleges that during the Class Period defendants knew but
misrepresented or failed to disclose to the investing public that: (1) the
Company had improperly recognized revenue under certain managed service
contracts; (2) the Company’s financial statements were not prepared in
accordance with Generally Accepted Accounting Principles; (3) the Company
lacked adequate internal and financial controls; and (4) as a result of the
foregoing, the Company’s financial statements were materially false and
misleading at all relevant times.

On February 26, 2013 Accretive announced that it will postpone the release of
the Company’s financial results for the fourth quarter and full year 2012
because it is evaluating the timing of revenue recognition for its revenue
cycle management agreements. In addition, Accretive withdrew its financial
guidance previously provided on November 7, 2012. On this news, shares of
Accretive declined almost 20%.

To learn more about this action or if you purchased Accretive stock prior to
the Class Period and have any questions concerning this Notice or your rights
or interests with respect to these matters, please contact Michael Goldberg,
Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100,
Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite
2920, New York, New York 10168, at (212) 682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, (888) 773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, (212) 682-5340
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.